IR
IRMD.US Iradimed Co
- Market cap
- USD 1.09B
- P/E
- 45.6x
- P/B
- 10.24x
- ROE
- 22.0%
- Dividend yield
- 1.38%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IRMD.US undervalued?
Graham numberThe Graham number of Iradimed Co cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Iradimed Co fundamental analysis
No fundamental analysis for Iradimed Co yet.
Iradimed Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Iradimed Co
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detect…
Full company profileIradimed Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Iradimed Co annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 32.5M | 23.1M | 30.4M | 38.5M | 31.7M | 41.8M | 53.3M | 65.6M | 73.2M | 83.8M | 88.9M |
| Gross Profit | 26.3M | 17.5M | 23.2M | 29.7M | 23.6M | 32.0M | 41.3M | 50.2M | 56.3M | 64.3M | 67.2M |
| Operating Income | 10.9M | 1.29M | 6.00M | 8.65M | -756K | 9.82M | 15.6M | 20.0M | 22.0M | 26.1M | 29.0M |
| EBITDA | 11.2M | 2.71M | 7.30M | 9.89M | 583K | 11.2M | 16.3M | 20.0M | 25.1M | 29.5M | 31.6M |
| Net Income | 7.21M | 500K | 6.30M | 9.63M | 1.37M | 9.33M | 12.8M | 17.2M | 19.2M | 22.5M | 23.4M |
| EPS | 0.60 | 0.04 | 0.52 | 0.78 | 0.11 | 0.74 | 1.02 | 1.35 | 1.50 | 1.75 | 1.82 |
| Balance Sheet | |||||||||||
| Total Assets | 37.2M | 39.0M | 48.4M | 66.7M | 71.1M | 82.9M | 85.5M | 92.2M | 98.3M | 109M | 121M |
| Total Liabilities | 5.31M | 6.08M | 6.50M | 11.2M | 9.68M | 10.7M | 11.8M | 20.7M | 11.5M | 14.2M | 14.6M |
| Shareholders' Equity | 31.9M | 32.9M | 41.9M | 55.5M | 61.4M | 72.2M | 73.7M | 71.4M | 86.8M | 94.6M | 106M |
| Cash & Short-term Investments | 25.7M | 26.3M | 34.4M | 46.3M | 52.0M | 62.5M | 58.0M | 49.8M | 52.2M | 51.2M | 63.3M |
| Total Debt | - | - | - | 2.96M | 2.72M | 2.48M | 2.21M | 2.04M | 155K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 9.41M | 3.42M | 7.38M | 10.2M | 5.82M | 11.3M | 10.0M | 13.5M | 25.6M | 24.9M | 28.3M |
| Capital Expenditure | 1.52M | 825K | 265K | 486K | 637K | 742K | 1.87M | 8.01M | 8.01M | 7.77M | 957K |
| Free Cash Flow | 7.88M | 2.59M | 7.11M | 9.75M | 5.18M | 10.5M | 8.17M | 5.46M | 17.6M | 17.2M | 27.3M |
| Ratios | |||||||||||
| ROE | 22.6% | 1.5% | 15.0% | 17.3% | 2.2% | 12.9% | 17.4% | 24.1% | 22.2% | 23.8% | 22.0% |
| ROA | 19.4% | 1.3% | 13.0% | 14.4% | 1.9% | 11.3% | 15.0% | 18.7% | 19.6% | 20.7% | 19.3% |
| Net Profit Margin | 22.2% | 2.2% | 20.7% | 25.0% | 4.3% | 22.3% | 24.1% | 26.2% | 26.3% | 26.8% | 26.3% |
| Debt to Equity | - | - | - | 0.05x | 0.04x | 0.03x | 0.03x | 0.03x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Iradimed Co dividends
- Dividend yield
- 1.38%
- Forward dividend
- 0.80 USD
- Payout ratio
- 66.9%
- Ex-dividend date
- Nov 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 15.0M | 1.17 | 66.9% |
| 2024 | USD 13.7M | 1.07 | 71.1% |
| 2023 | USD 13.2M | 1.04 | 76.9% |
| 2022 | USD 12.6M | 0.99 | 97.9% |
| 2021 | USD 12.6M | 1.00 | 134.7% |
| 2020 | USD 12.6M | 1.01 | 917.4% |
| 2019 | USD 12.6M | 1.02 | 130.4% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Iradimed Co
- Insiders 35.24%
- Institutions 62.94%
- Public & others 1.82%
- Shares outstanding 12.8M
- Free float 8.33M
Top funds holding IRMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 264K | 2.07% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 206K | 1.61% | 0.00% | Oct 2026 |
| Virtus KAR Small-Cap Growth I | 137K | 1.07% | -1.96% | Jun 2026 |
| Fidelity Small Cap Index | 92.6K | 0.72% | 0.00% | Aug 2026 |
| JNL Multi-Manager Small Cap Growth A | 86.6K | 0.68% | -15.57% | Sep 2026 |
| Nuveen Quant Small Cap Equity R6 | 84.1K | 0.66% | +38.19% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 80.7K | 0.63% | -0.38% | Oct 2026 |
| T. Rowe Price Small-Cap Stock | 71.5K | 0.56% | -0.57% | Sep 2026 |
| Fidelity Advisor Small Cap I | 65.3K | 0.51% | 0.00% | Aug 2026 |
| BlackRock Advantage Small Cap Core Instl | 56.3K | 0.44% | +1.32% | Sep 2026 |
| DFA U.S. Small Cap I | 56.2K | 0.44% | 0.00% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 55.3K | 0.43% | -51.27% | Sep 2026 |
| Vanguard Russell 2000 ETF | 49.4K | 0.39% | +1.13% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 44.4K | 0.35% | +0.22% | Oct 2026 |
| DFA US Micro Cap I | 44.4K | 0.35% | 0.00% | Sep 2026 |
| AB Small Cap Core Z | 43.5K | 0.34% | +52.33% | Sep 2026 |
| Dimensional US Small Cap ETF | 42.1K | 0.33% | 0.00% | Oct 2026 |
| Victory Small Cap Stock | 41.4K | 0.32% | +5.75% | Sep 2026 |
| CREF Total Global Stock Account R3 | 39.8K | 0.31% | 0.00% | Sep 2026 |
| iShares US Medical Devices ETF | 39.4K | 0.31% | -1.13% | Oct 2026 |
Top institutions holding IRMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 968K | 7.57% | +0.00% | Jun 2026 |
| Kayne Anderson Rudnick Investment Management LLC | 397K | 3.10% | +13.65% | Jun 2026 |
| Copeland Capital Management, LLC | 382K | 2.99% | -2.51% | Sep 2026 |
| Vanguard Capital Management, LLC | 365K | 2.85% | +1.76% | Jun 2026 |
| Renaissance Technologies Corp | 351K | 2.74% | -11.11% | Sep 2026 |
| T. Rowe Price Investment Management,Inc. | 319K | 2.49% | +24.15% | Jun 2026 |
| Geode Capital Management, LLC | 290K | 2.27% | +1.24% | Jun 2026 |
| Nine Ten Capital Management LLC | 257K | 2.01% | -23.30% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 231K | 1.81% | +0.71% | Sep 2026 |
| State Street Corp | 222K | 1.73% | +8.30% | Jun 2026 |
| The Goldman Sachs Group Inc | 214K | 1.67% | +8.19% | Jun 2026 |
| Two Sigma Investments LLC | 183K | 1.43% | +10.40% | Jun 2026 |
| Qube Research & Technologies | 157K | 1.23% | +88.38% | Jun 2026 |
| Royal Bank of Canada | 148K | 1.16% | +397.11% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 144K | 1.13% | +832.14% | Jun 2026 |
| Northern Trust Corp | 134K | 1.05% | +8.11% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 126K | 0.99% | -15.88% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 125K | 0.98% | +2.39% | Jun 2026 |
| Ranger Investment Management LP | 98.3K | 0.77% | -11.47% | Jun 2026 |
| Bridge City Capital, LLC | 97.0K | 0.76% | +36.50% | Sep 2026 |
Iradimed Co company profile
- Company name
- Iradimed Co
- Ticker
- IRMD.US
- Exchange
- USA Stocks
- Listed since
- Jul 16, 2014
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 166
- Fiscal year end
- December
- Address
- 12705 Ingenuity Drive, Orlando, FL, United States, 32826
- Phone
- 407 677-8022
- Website
- iradimed.com
About Iradimed Co
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.
Iradimed Co management
7- Mr. Roger E. SusiFounder, Chairman, CEO & President · born 1953
- Mr. John F. GlennCFO & Corporate Secretary · born 1962
- Mr. Jeff ChiprinChief Commercial Officer · born 1966
- Mr. Randy WaddellVice President of Worldwide Sales & Marketing
- Mr. Chris WilliamsonExecutive Vice President of Continuous Improvement & Information Technology
- Mr. Matt GarnerController
- Mr. Lynn NeuhardtVice President of Research & Development